tickerreport.com
Positivewww.tickerreport.com ·
proqr therapeutics nasdaqprqr downgraded to strong sell rating by wall street zen
EPU_POLICY_REGULATORYTAX_DISEASE_EPIDERMOLYSIS_BULLOSAWB_1614_NUTRITIONAL_PROGRAMSWB_1609_FOOD_AND_IN_KIND_TRANSFERS
Topic context
This topic has been covered 250632 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSingle-company analyst downgrade based on revenue miss and weak financials. No broader sector or supply-chain impact; commercial mechanism is limited to PRQR's stock valuation and investor sentiment. No product/commodity price, scarcity, or margin channel identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- ProQR Therapeutics downgraded from hold to strong sell by Wall Street Zen on May 17, 2026.
- Stock opened at $1.59, market cap $167.52 million, 52-week range $1.33-$3.10.
- Q1 2026 EPS ($0.15) in line with estimates, but revenue $2.35M missed $5.19M estimate.
- Institutional ownership 32.65%.
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
economictimes.indiatimes.com
missiles over dubai rattle the gulfs billion dollar money machine dubai property uae deal ipo market
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
fool.com
halozyme halo q1 2026 earnings transcript
timesofindia.indiatimes.com